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ABSTRACT 
 
Introduction: 
Osteoarthritis (OA) of the knee is characterized by chronic pain, cartilage 
matrix degradation, deterioration of the mechanical properties of the synovial 
fluid, bony osteophyte formation, and episodic inflammation. Compared to 
healthy joints, the synovial fluid in joints affected by OA can be characterized 
by both diminished molecular weight and concentration of its primary 
functional constituent, hyaluronan. 
 
Hyaluronan is a polysaccharide consisting of repeating linear dimers of N-
acetylglucosamine and glucuronic acid. It is physiologically ubiquitous in the 
animal kingdom, in particular existing as a large molecular weight substance in 
bony joints where small quantities serve as both a lubricant and a transport 
medium for nutrients, proteins, and degradation products related to joint tissue 
metabolism. Lower molecular weight hyaluronan found in osteoarthritic joints 
fails to retain its viscoelasticity and ability to withstand shear forces, both small 
(normal joint movement) and large (high impact forces). As a result, joint 
surfaces can become progressively damaged when endogenous hyaluronan 
production is reduced by disease. 
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Corticosteroids may work through influencing levels of collagenase and 
aggrecan, as well as matrix metalloproteinases and proinflammatory cytokines. 
 
No single cause of OA found no far. Multiple factors that might cause OA 
includes, genetic predisposition, age, injury prior to adulthood, microtrauma, 
body weight, stress on the joint, occupational task i.e., repetitive knee bending, 
heavy lifting and previous surgery of joint.
1-3 
 
Aims and Objectives: 
To compare the functional outcome and pain relief of Intra articular Hylan GF-
20 Vs. Methyl Prednisolone Acetate for Grade II Osteo Arthritis – Knee. 
Study Centre: 
Government Institute of Rehabilitation Medicine, KK Nagar, Chennai-600 083. 
Duration of study: 
18 months (March-2015 to August-2016) 
Study design: 
Prospective Single blinded Cohort study 
- Subjects will be randomized by systematic random sampling, according 
to registration number of the study 
- Odd numbers (Group A)will be treated with Hylan GF-20 
- Even numbers (Group B) will be treated with Methyl Prednisolone 
Acetate. 
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Methodology: 
- Patients will be given test dose of 0.5ml of Lignocaine 2% 
- They will be taken to Operation theatre and parts will be cleaned with 
Betadine and drapped with sterile towel 
- Under aseptic precautions, Lignocaine 2% will be injected to anesthetise 
the injection site 
- By following randomization procedure, either Hylan-
GF20(48mg)/methyl prednisolone acetate(40mg) will then be infiltrated 
into the knee joint space after confirmation by aspiration technique by 
infero lateral approach 
- After infiltration the subjects will be observed for 15 minutes for 
adverse reactions 
- Subjects will be asked to report immediately in case of adverse reactions 
like post injection flare (increased pain, swelling)/hypersensitivity 
reactions etc., 
- Also they will be given 3 days of analgesics and antibiotics. 
Inclusion criteria: 
 Age > 45 years 
 Grade II osteoarthritis knee by Kellgren-Lawrence grading 
 Knee pain with failed conservative treatment for 1 month 
 Stiffness:<30mts 
 Crepitus 
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 Bony tenderness 
 Bony enlargement 
 No palpable warmth. 
 
Exclusion criteria: 
 Post Operative cases 
 Cellulitis / Infections 
 Any implants inside. 
 Associated with DVT calf muscles   
 Non co-operative patient     
 Low I.Q Patients /psychiatric patient 
 Trauma 
 Meniscal injury 
 Anterior/Posterior cruciate ligament injury 
 Medial/Lateral collateral ligament injury 
 Bursitis 
 Rheumatoid arthritis 
 Pseudogout 
 Other grades of osteo arthritis knee 
 
Sample size: 
Approx 30+30 
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Product/Investigation details: 
Investigations: 
FBS, PPBS, X-ray knee-AP and Lateral 
Product details: 
Methylprednisolone acetate – 80mg 
Hylan-GF 20 – 48mg 
Data collection and Methods: 
- Subjects will be randomized according to registration number of the 
study 
- Odd numbers (Group A) will be treated with Hylan GF-20 
- Even numbers (Group B) will be treated with Methyl Prednisolone 
Acetate 
- Case History age, sex, duration of pain will be collected.  
Anthropometric measurements height and weight of the patient will be 
collected. 
- They will be assessed with pre procedural and post procedural 
o pain score using Visual Analog Score (VAS) 
o WOMAC-C score 
o Range of Movements of Knee 
- The assessment will be analysed using SPSS software (version 21) 
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Results: 
- There were 23 males and 37 females enrolled in the study, among which 
14 males (60.9% of total males) and 16 females (43.2% of total females) 
were enrolled in Hylan group and 9 males (29.1% of total males) and 21 
females (56.8% of total females) were enrolled in the steroid group. 
- 49 patients had pain along anterior aspect of knee joint and 11 patients 
had pain along medial joint line. Among hylan group, 25 patients had 
pain along anterior aspect and 5 had pain along medial joint line. In 
steroid group, 24 had pain along anterior aspect and 6 had pain along 
medial joint line. 
- Pain was assessed using Visual Analog Scoring (VAS) in this study. It 
showed significant pain relief with hylan group over due course of time. 
In steroid group, there was initial pain response till 8 weeks after the 
treatment, but later the pain score started to show upward trend in later 
weeks. In conclusion, pain relief was better in hylan group than steroid 
group with p value <0.05 in all the follow up period except 8
th
 week. 
- Functional assessment after the treatment was done using WOMAC 
score (The Western Ontario and McMaster Universities Arthritis Index) 
and improvement in range of movements of the knee in this study. It 
showed significant functional improvement with hylan group over due 
course of time. In steroid group, there was initial better response till 8 
weeks, but later the functional ability started to reduce in later weeks. In 
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conclusion, functional improvement as per WOMAC score was better in 
hylan group than steroid group with p value <0.05. 
- Functional assessment after the treatment was also done using range of 
movements (ROM). It showed significant improvement in ROM with 
hylan group over due course of time and remained stable in 12
th
 and 26
th
 
weeks. In steroid group, there was initial better response around 4
th
 and 
8th weeks, but later ROM got reduced and did not show any further 
change in later weeks. In conclusion, functional improvement as per 
ROM was better in hylan group than steroid group with p value <0.05. 
 
Conclusions: 
 Intra articular Hylan GF-20 shows statistically significant improvement in 
Pain in analyzing the patients with Visual Analog Score (VAS) 
 Similarly, there is improvement in range of movements and WOMAC score 
(C domain) in hylan group 
 For steroid group, there is initial statistical improvement upto 8 weeks in 
pain and other functional components, but after 8 weeks, there is no clinical 
improvement 
 Hence Hylan GF-20 can be considered as an important therapeutic measure 
in the management of OA knee. 
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INTRODUCTION 
 Osteoarthritis is mainly concerned with disease of synovial joints and its 
surrounding soft tissues. The main pathology involves progression of articular 
cartilage and the formation of bone at the margins of the joint.
1
 
 
EPIDEMIOLOGY:  
 Osteoarthritis is an extremely common condition after 40 yrs of age. It is 
wide spreading in adults older than 65 and affects men more than women before 
the age of 50 and reverses after the age of 50. More than 20 million people are 
affected by OA in U.S. It is the most common leading cause of chronic disability
1
. 
In India, studies show that the prevalence of osteoarthritis is as high as in any 
other part of the world.  WHO Technical Report Series – 919 shows prevalence of 
osteoarthritis of the knee per 1,00,000 population in India.  Indian statistics 
revealed that 4644 males and 6587 females in 45-59 age group and 2247 females 
in 35-44 age group has osteoarthritis based on clinical Epidemiology. 
 
 In United States, osteoarthritis is second only to ischemic heart disease as a 
cause of work disability in men over age 50.  It has been estimated that about 
1,00,000 people in United States are unable to walk independently because of 
osteoarthritis of hip or knee.  Data from arthritis research campaign show that upto 
5,50,000 people in United Kingdom has severe osteoarthritis of knee.
2,3
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ETIOLOGY:  
 No single cause of OA found no far. Multiple factors that might cause OA 
includes, genetic predisposition, age, injury prior to adulthood, microtrauma, body 
weight, stress on the joint, occupational task i.e., repetitive knee bending ,heavy 
lifting and previous surgery of joint.
1,4,5
 
 
Progression of OA includes following factors: 
1. Loss of cartilage matrix which makes the joint most susceptible to injury 
2. Alterations to underlying bone associated with wear on the cartilage 
3. Formation of osteophytes 
4. Release of debris of cartilage or bony fragments into the joint 
5. Cartilage breakdown with synovial inflammation leads to release of cytokines 
and enzymes which exacerbate the cartilage damage. 
 
Signs and symptoms: 
Pain, swelling loss of ROM, bony deformity. 
OA is not associated with systemic features like RA 
Stiffness and crepitus. 
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Management: 
 
 
                
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Mild symptoms on presentation: 
 Physical medicine 
 Weight reduction 
 Patient counseling 
 Analgesics 
Moderate to Severe symptoms 
on presentation: 
 Physical medicine 
 Weight reduction 
 Patient counseling 
 NSAIDs 
 Chondro protective drugs 
 Anti resorptive agents 
Intra articular injections: 
 Cortico steroids 
 Visco supplementation 
Surgery: 
 Osteotomy 
 Arthroscopy 
 Arthrodescis 
 Patellectomy 
 Unicompartmental Joint Replacement 
 Total knee replacement 
 
Chart 1: Management of Osteo Arthritis – knee. 
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AIMS AND OBJECTIVES 
 
 To compare the functional outcome and pain relief of Intra articular Hylan 
GF-20 Vs. Methyl Prednisolone Acetate for Grade II Osteo Arthritis – 
Knee. 
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REVIEW OF LITERATURE 
 
Knee joint anatomy 
      Knee is the largest and most complex joint of the body. It is a compound 
synovial joint, incorporating two condylar joints between the condyles of femur 
and tibia and one saddle joint between femur and patella. The stability of the joint 
is maintained by number of factors: 
    1. Cruciate ligaments maintain antero posterior stability 
    2. The collateral ligaments maintain side to side stability 
    3. The weak capsular ligament was strengthened anteriorly by the medial and 
lateral patellar retinacula from vastusmedialis and lateralis, laterally by the 
iliotibial tract, medially by tendons of Sartorius and Semimembranosis and 
posteriorly by the oblique popliteal ligament 
    4. The role of iliotibial tract in stabilizing a partially flexed knee cannot be over 
emphasized 
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 The anatomical axes of the bone runs between the shaft of the femur and 
tibia, which is normally about 170-175 degree (obtuse, physiologic valgus angle). 
If any deviation in this angle results varus or valgus deformity, which predisposes 
to osteoarthritis knee while joint over loads. 
Figure 1: Anatomy of knee joint – AP view. 
Figure 2: Anatomy of knee joint – Lateral view. 
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Osteo Arthritis (OA) Knee: 
 OA knee is a degenerative joint disease occurring primarily in older 
persons, characterized by erosion of the articular cartilage, hypertrophy of bone at 
the margins, subchondral sclerosis and a wide range of biomechanical & 
morphological alterations of the synovial membrane and the joint capsule. The 
main clinical symptoms are pain &stiffness after prolonged activity. In 
industrialized societies OA knee was the leading cause of physical chronic 
disability, increase in health care utilization & impaired quality of life.
6
 
Figure 3: Axes of knee joint. 
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Major risk factors affecting degree of risk for developing OA knee include age, 
joint location, obesity, genetic predisposition, joint malalignment, trauma & 
gender. 
 
 
 
Figure 4: Pathological Changes in OA knee. 
Table 1: Risk factors for OA knee.
6
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 The impact of arthritic conditions was expected to grow as the population 
both increases & ages in the coming decades.
6
 
 
Definition: 
 According to Harrison’s Principles of Internal Medicine, osteoarthritis 
represents failure of the diarthrodial (movable, synovial lined) joint.  Definitions 
which erroneously described it as a degenerative disease are no longer acceptable. 
Osteoarthritis differs from simple wear and tear of joints innumerous ways. 
 It is not necessarily age related. 
 It is asymmetrically distributed and often localized only in one part of the 
joint 
 It is more clearly related to impact loading than to frictional wear. 
 It progresses steadily, often resulting in pain and dysfunction of the joint. 
 It is not necessarily accompanied by any systemic illness. 
 Although there are sometimes signs of inflammation, it is not primarily an 
inflammatory disorder. 
 It is more a process than disease, occurring in almost any condition that 
causes disparity between the mechanical stress applied to articular cartilage 
and the ability of the cartilage to withstand that stress. 
In addition to these primary processes, there are ―modifiers‖ that influence the rate 
of pathlogic and clinical progression like recurrent synovitis, avascular necrosis of 
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subchondral bone, joint instability and prolonged use of powerful anti 
inflammatory preparations, which may depress bone healing
7
. 
 
Classification: 
 Clinically, osteoarthritis may be classified as Primary or idiopathic and 
secondary. 
 
Primary (idiopathic) 
Knee (medial, lateral, patellofemoral) 
 
Secondary 
 Dysplastic 
 Post-traumatic 
 Structural failure 
 Post-inflammatory 
 Endocrine and metabolic 
 Connective tissue 
 Etiology obscure. 
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Race  
 Prevalence of osteoarthritis of knee is similar among Europeans and 
Americans.  Whether these differences are genetic or due to differences in joint 
usage related to lifestyle or occupation is unknown.
8
   
 
Genetic factors 
 The relation of heredity to osteoarthritis is less ambiguous.  First-degree 
relatives of diseased females are two to three times likely to develop osteoarthritis, 
due to the similarity in the genes encoding structural proteins of extracellular 
matrix of cartilage.  Mercer is of the opinion that joint laxity may also be a feature 
in familial predisposition to osteoarthritis.  According to Kelley, a positive family 
history was often elicited in patients with generalized osteoarthritis and it was a 
polygenic disorder.  At least four genetically determined mechanisms have been 
postulated: 
 A genetic defect in type II collagen may directly affect cartilage structure. 
 A heritable trait, as in alkaptonuric ochronosis may indirectly alter the 
mechanical properties of articular cartilage. 
 Inherited forms of epiphyseal dysplasia may result in joint incongruity and 
eccentric articular stresses. 
 Generalized characteristics such as obesity and excessive joint laxity, may 
adversely affect joint loading. 
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 Evidence from various studies shows that, there is increased concordance 
for osteoarthritis in monozygotic twins compared with dizygotic twins, indicating 
the increased genetic susceptibility to the disease.
9,10
 
 
 In 1972 Radin et al., proposed a hypothetical model to explain the 
mechanical basis for osteoarthritis.  The model, still quite controversial, accounts 
for changes observed in joints with signs of osteoarthritis, and was based on 
wolff’s law, outlining the response of skeletal tissue to imposed stress.11 
 
 
IMPULSIVE LOADING 
 
TRABECULAR MICROFRACTURE 
 
BONE REMODELLING 
 
RESULTANT BONE STIFFENING 
 
INCREASED STRESS ON ARTICULAR CARTILAGE 
 
JOINT DEGENERATION 
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 Impulsive loading is an external force that reaches a high magnitude in a 
short time.  According to Wolff’s law, bone remodels in response to the imposed 
stress. 
  
 In summary, a variety of indirect evidence supports the view that physical 
changes in the subchondral bone may be important in osteoarthritis and that at 
least a portion of this issue is related to an alteration in a hydraulic factor in the 
trabecular tissue.  
 
Normal cartilage 
      Normal healthy articular cartilage is composed of extra cellular matrix and 
chondrocytes. Water content is about 65-80% of matrix by weight, type 2 collagen 
(10%), proteoglycans, non collagenous protein and glycoproteins the remainder. 
Chondrocytes secrete matrix and present through matrix and concentrated in deep 
layers. The superficial layer contains highest amount of the water and collagen and 
giving this zone the greatest tensile stiffness and strength and ability to resist 
shearing force. Proteoglycans contain protein core and glycosaminoglycans 
(hyaluronic acid and chondroitin sulfate). Proteoglycans are concentrated in 
middle and deep zones. Cartilage contains no nerves, blood vessels or lymphatics. 
It receives its nutrition and elimination of waste via diffusion through synovial 
fluid by facilitated imbibitions. 
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Role of cartilage 
 It decreases friction between articular joint surfaces distributing static and 
dynamic joint forces to underlying bone and absorbing shock. 
 Cartilage’s shock absorbing effect is minimal (1%), subchondral bone 
(30%) and also peri articular muscles
11,12
. These joint structures with ligaments, 
menisci, capsule, synovium and synovial fluid give protection to joint from regular 
wear and tear and damaging forces
11-14
. Cyclical loading of joint enhances 
proteoglycan synthesis and concentration.
15 
 
Biomechanics and disease mechanisms of OA: 
 
Figure 5: Pathogenesis of OA knee. 
knee 
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 The reparative process of cartilage differs from other vascularised tissues 
was that it was avascular. The healing response has three phases in vascularised 
tissues.
16,17
 
Necrosis 
Inflammation 
Repair  
Cartilage undergoes the initial phase of necrosis in response to injury was less, 
because it was insensitive to hypoxia.
16,17
 
 
 In partial thickness injuries the inflammatory phase was absent because that 
don’t cross the tidemark and the repair phase was severely limited given the lack 
of vascularity and a preceeding inflammatory response and no local hyperemia, no 
fibrosis network was produced, no subsequent clot  develops to act as a scaffold 
for the ingrowth of repair tissue, no mediators, nor cytokines were released, that 
enhances the cell migration, proliferation and no inflammatory cells(which has 
mitotic and reparative potential) were recruited.
17,18
 
 
 In lesions with partial thickness injuries, the burden of repair process was 
mainly depending upon the chondrocytes, called intrinsic repair.
19
 
  
 In full thickness injuries, chondrocytes undergo extrinsic repair via 
differentiation and proliferation of mesenchymal stem cells from para articular 
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connective tissues and forms fibrocartilage with inadequate biomechanical 
properties. 
 
Three categories 
 Micro damage or repetitive blunt trauma to the matrix and cells.   
 Repetitive blunt trauma produces a surface loss of proteoglycans and 
increased chondrocyte metabolic activity. 
 
Early stages: increased hydration, cellular degeneration, disruption of the 
collagen ultrastructure resulting in marked variation in the size and arrangement of 
fibers, fissuring and ulceration of articular surface, thickening of subchondral bone 
& softening of the cartilage with loss of its compressive and tensile stiffness. 
Micro injury releases enzymes, proinflammatory mediators- nitric oxide, TNF, 
IL1. It causes further degradation of surrounding matrix tissue. Eventually the 
material properties of cartilage were altered, which in accelerates the degenerative 
process. If discontinue the repetitive trauma which restores the matrix components 
and reverses all the degradative process.
18,20
 
 
 Partial thickness injuries or superficial injuries or chondral fractures (that 
do not cross the subchondral plate). Osteochondral (full thickness or deep, 
penetrating) injuries. If damage that cross the articular cartilage tidemark disrupts 
the subchondral plate, it induces three phases of repair response, in which the 
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defect will be filled by hematoma. Then it causes organization of fibrin clot with 
the use of TGF-B, PDGF, IGF, BMPS and later converted into 
fibrocartilage.
17,20,21
 
 After 6-8 weeks of injury the repair tissue contains increased amount of 
chondrocyte like cells surrounded by matrix consisting of proteoglycan and type II 
collagen with lesser amount of type I collagen.
22
 
 Cells in deeper layer differentiate into osteoblast & subsequently undergo 
enchondral ossification to heal the subchondral defect
18
. 
 One year after injury there was a transition of type I collagen from type 
II
23,24
. 
 The repair tissue consists of mixture of fibro & hyaline cartilage. Fibro 
cartilaginous repair is susceptible to early degenerative changes because it lacks 
the biomechanical properties to withstand joint loads.
25
 
 
Subchondral cysts: 
 It contains myxoid, fibrous or cartilaginous tissue along with bone marrow. 
These lesions identified by MRI and associated painful OA knee. 
 
 
OSTEOPHYTE FORMATION: 
 Osteophytes are fibrous, cartilaginous, or bony in composition and 
marginal prominences are palpable and often tender in patients with OA knee. 
18 | P a g e  
 
Theories are;  
1. Due to increased vascularity in degenerated cartilage 
2. Venous congestion from subchondral cyst 
3. Thickened subchondral trabeculae 
4. Continued sluffing of articular cartilage 
Osteophytes contributes the production of pain and functional loss. 
 
 
 
 
 
Figure 6: Histopathological feature of Osteoarthritis: Cartilage, Cleft and fibrillation. 
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Signs and symptoms: 
Pain, swelling loss of ROM, bony deformity. 
OA is not associated with systemic features like Rheumatoid Arthritis. 
Stiffness for less than 30 mts 
Crepitus. 
 Knee OA more commonly affects the medial joint due to the higher weight 
bearing load on that compartment. As a result, narrowing of joint space leads to 
pseudolaxity of medial collateral ligament, stretching of the lateral collateral 
ligament counterpart, and genu varus deformity. Valgus deformity occurs in lateral 
compartment involvement. 
     A flexion deformity of knee occurs due to pain, leads to functional leg 
length discrepancy, decreased step length and quadriceps muscular fatigue and 
strain. 
 
Functional difficulties: 
Climbing stairs and squatting: 
Over all OA knee can impose functional limitations equal to heart disease, CHF, 
COPD and accounts for the substantial proportion of the burden of disability 
among community living elders. OA is a leading cause of disability and major 
contributor to work related disability, productivity and absenteeism.  
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Pain generators 
 Focal Synovitis 
 Synovial effusion 
 Subchondral bone pain receptors 
 Periarticulars tendons  
 Bursae 
 Loose bodies  
 Varus or valgus deformity 
 Weight issues 
 Emotional impact of chronic pain 
 
CLASSIFICATION & CRITERIA OF OA KNEE:  
No standard definition of OA has been used. OA knee is diagnosed by 
radiographic evidence by Kellgren-Lawrance grading and clinical diagnosis by 
ACR (American College of Rhematologic criteria). Kellgren-Lawrance grading is 
the most commonly used system for research activities in OA knee.
11,26
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KELLGRAN-LAWRANCE GRADING 
 
 
 
 
ACR CRITERIA: 
CLINICAL & LABORTARY: 
Knee pain with atleast 5 of the following (92% sensitive, 75% specific) 
1. Age > 50 years 
2. Stiffness less than 30 minutes 
3. Bony tenderness 
4. Bony enlargement 
5. No palpaple warmth 
6. ESR (Westergren method < 40 mm/hr) 
7. Rhematoid factor (<1:40 ratio) 
8. Synovial fluid signs- clear, viscous, WBC count <2000 cu.mm. 
Table 2: Kellgren – Lawrence Grading of OA knee. 
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CLINICAL AND RADIOGRAPHIC: 
Knee pain plus atleast one of the following (91% sensitive, 81% specific) 
1. Age >50 years 
2. Stiffness <30 minutes 
3. Ccrepitus Plus osteophytes. 
 
CLINICAL CRITERIA: 
Knee pain plus atleast 3 of the following (95% sensitive, 69% specific) 
1. Age >50 years 
2. Stiffness < 30 minutes 
3. Crepitus 
4. Bony enlargement 
5. No palpable warmth 
6. Bony tenderness. 
 
        There is no association between radiological findings and patient symptoms 
(pain). Muscles strength and pain are the most common reason of functional loss 
than radiological findings.
13,27
 
 
Investigations: 
 Plain X ray – antero posterior and lateral view is the investigation of choice 
for OA knee.  
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 Ultrasound is used to visualize the bony and soft tissue structures and is 
more sensitive in diagnosing in effusion, synovitis and early osteophytes in OA 
knee
28
. 
 High resolution MRI is used to early structural changes and pathology in 
pain sensitive structures.
11,28 
 
 
Radio nuclide scanning: 
    Scanning with TC 99M shows increased activity during the bone phase in 
the subarticular region of any affected joint. It may be apparent, years before the 
typical Xray changes appear and reflects the vascular reaction and osteoblastic 
activity that are present even in the early stages of cartilage loss.
29 
 
Complications of OA knee: 
1. Capsular herniation (stretching by effusion) encountered most commonly as a 
Baker’s cyst. 
2. Loose bodies (cartilage / bone fragments occasionally resulting in locking of the 
joint). 
3. Genu varus or valgus deformities. 
4. Joint instability. 
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Disease onset and course 
   OA starts in insidious onset, and usually asymptomatic in individuals with 
only aneural cartilage is involved. Pain is initially episodic and aggravated by 
specific activity. In later stage pain becomes chronic, dull ache and accentuated 
with episodic severe pain. 
 
Prognosis 
   OA is a slow progressing disease that can be self limiting or progress to 
advanced joint damage and soft tissue damage leading to complete failure of that 
joint. 
 
Management: 
Pharmacological treatment 
Non pharmacological treatment 
 
Pharmacological management: 
Goals: 
       Relieve pain and decrease inflammation and maintain or improve mobility 
and minimize disability. 
1.    Oral analgesic 
2.    NSAIDs 
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3.   Corticosteroid injection-used for acute episodes with moderate pain relief. 
Those above said drugs are used as primary medications in OA knees. 
 
4. Visco supplementation-used in mild to moderate OA knee, which improves 
pain, stiffness and improves physical functions. 
5. Chondroprotectives-glucosamine sulfate and chondroitin sulfate. Long term 
follow up study with 1500mg/day for 12 months revealed in OA knees patients 
less likely to undergo total knee replacement at 5 years. 
6. Topical analgesics-contains capsaicin (decrease pain about 33% if applied to 
joints 4 times daily).Other topical agent contains Diclofenac - an alternate 
adjunctive treatment in OA knee. 
 
 Acetaminophen is an oral analgesic, is the drug of first choice. It has no 
toxicity in recommended doses up to 4gm/day. However it has no anti 
inflammatory effect. In patients with symptomatic OA knee it has minimal effect 
on pain and no significant effect on stiffness or physical function. Further, 
acetaminophen use can lead to liver toxicity and less commonly kidney toxicity in 
patients who is an alcoholic and also there is increasing evidence of hospitalization 
due to GI perforation, peptic ulceration and bleeding with acetaminophen use of 
more than 3 gm/day.
30-34
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 NSAIDs –who are not responding to acetaminophen and non 
pharmacological therapy, NSAIDs may be used in combination with 
acetaminophen, and should be kept lower doses to avoid GI problem.
11,33 
   
Non pharmacological treatment: 
     The chronic nature of the disease (arthritis) plans the treatment by plan of care 
that includes patient education and self management. Hence rehabilitation of 
arthritis requires comprehensive and coordinated efforts by physiatrist and 
physiotherapist.
35
 
 Currently no studies that revealed such programmes improve the 
psychologic health, symptoms of health related quality of life or that they 
significantly alter health care use.
36-38 
 
Rehabilitative management: 
General goals and outcomes of OA knee:  
Reduction of impact of impairments by 
 Decreasing the pain 
 Improvement in joint ROM for functional activities 
 Improve the muscle strength for functional activities 
 To achieve the joint stability 
 Prevention of joint deformity 
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Reduction of biomechanical stress on affected joints: 
 Improve the endurance for functional activities 
 
Physical function by 
 To promote the independency in dressing, transfers and self care 
 To improve the efficiency and safety of gait pattern and balance 
 To maintain the adequate strength of musculoskeletal system, cardio 
vascular fitness  
 
Improvements in health status and quality of life by 
 Educating the patient, family members, and care givers for self 
management and joint protection 
Exercise, Equipment, and education treatment options in OA knee. 
 
Non-pharmacologic measures:  
 Reduction of joint loading 
 Correction of poor body mechanics 
 Correction of poor posture and posture support 
 Obese and overweight patients should be counseled to lose weight 
 Patellar taping 
 Wedged insoles and orthoses. 
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 Lateral wedged insole with an angle 5 to 10 (on a frontal section) is shown 
to be helpful for treatment of medial compartment knee osteoarthritis 
providing a ―medical osteotomy‖.  Decreased excessive loading on the 
medial surface and decreased stretching of the lateral collateral ligament 
obtained by the insole may be effective in reduction of pain.  Insole is much 
more effective for patients with mild osteoarthritis than for those with 
advanced disease.  A polypropylene mesh insole is practical, washable and 
may last about 2 years (i.e., approximately twice as long as a leather 
insole). 
 
 The use of elastic bandages, neoprene sleeves or canvas braces has been 
shown to improve proprioception about the knee and to diminish arthrogenous 
muscle inhibition.  Many patients note an increased sense of stability and strength 
and diminished pain with these knee orthoses.
39,40
 
 
Exercises: 
 Aerobic exercises 
 Whole body physical activity exercise 
 Isometric Quadriceps exercise 
 Straight Leg raise exercise 
 Hip abductor and adductor strengthening exercise 
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 Exercise helps to keep joints flexible, increase muscle strength, control 
weight and strengthen bone and ligaments. 
 
Physical Modality: 
 Paraffin wax bath 
 Infra red radiotherapy (IRR) 
 Trans cutaneous electrical nerve stimulation (TENS) 
 Short wave diathermy (SWD). 
 
Equipment: 
      Adaptive for ADL, Assistive for ambulation, Appropriate footwear or insoles 
 
Education: 
     Self management, weight loss, activity management or joint protection, 
social support, stress management/relaxation. 
 
Intraarticular cortico steroids: 
 Hydrocortisone was introduced for intraarticular injection in 1951.
41
 
 But their use in OA knee was controversial. However early studies in mice, 
rat & rabbit suggested that multiple corticosteroid injections might alter the 
cartilage, protein synthesis & consequently damage the cartilage.
42-46
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Methyl prednisolone acetate: 
     Despite there is no role for systemic steroid in OA knee, local intra articular 
corticoid preparations can be used.  It is intermediate acting cortico steroid. 
Injection may be repeated 2-3 times a year, but have the potential to cause joint 
destruction. 
 
MECHANISM OF ACTION: 
Down regulate expression of adhesion molecules. 
Reduce the cellular infiltration in to the joint and subsequent inflammation. It 
inhibits the prostaglandin synthesis and decrease the activity of collagenase and 
other enzymes. Saxne et al study explained about effects on therapy on cartilage 
metabolism that reduce the production of IL1, TNF alpha & proteases which 
might degrade the cartilage.
47
 
 
Metabolism: 
 Injected steroids can be detected in synovial fluid within 48 hours after 
injection. The rate of absorption of steroid was mainly depending upon the 
solubility of the compound.
48
 
 So after injection, we ask the patient to limit their activity as it delays the 
escape of the steroids and minimize the systemic side effects. 
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Relative Contraindications: 
 Local infection 
 Anticoagulant therapy 
 Uncontrolled diabetes mellitus 
 Severe joint destruction & deformity 
 Obesity. 
 
Complications: 
 Complications of intraarticular therapy are rare even though there were 
infection, post injection flare (local adverse reactions, reversible), localized 
subcutaneous or cutaneous atrophy, periarticular calcifications, overuse of steroids 
giving raise to charcot like arthropathy.
41,49-51
  
 Methyl Prednisolone has been chosen for intra articular steroid injection in 
this study as it is more efficacious steroid and has good short term analgesia.
52
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Hylan GF-20: 
 
 
 
 
 Hylan GF-20 is a high molecular visco supplement. It was cross linked 
derivative of hyaluronan which naturally occurs in synovial fluid. In OA knee, 
patients have low molecular weight hyaluronan which fails to retain its visco 
elasticity and ability to with stand shear forces. The mechanism of action of 
hyaluronan products in humans has not been established. However, a combination 
of multiple effects proved including restoration of joint rheology, anti nociceptive 
effects, anti inflammatory effects and normalisation of endogenous hyaluronan 
synthesis.
53,54
 
 
 Hylan GF-20 substance chemically cross linked and formed. It has two 
different forms – Hylan A and Hylan B. Hylan A is a fluid by volume, comprises 
Figure 7: Molecular structure of Hylan GF-20. 
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80% of Hylan GF-20, while the other 20% of Hylan Gf-20 is comprised of Hylan 
B – a gel. This composition makes this, identical to human synovial fluid – both in 
molecular weight and visco elasticity. 
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MATERIALS AND METHODS 
 
Study Centre: 
 This study was conducted at Government Institute of Rehabilitation 
Medicine, KK Nagar, Chennai-600 083. 
 
Duration of study: 
 The study period is for 18 months (March-2015 to August-2016), with 
minimum follow up of 26 weeks. 
 
Study design: 
This is a prospective Single blinded Cohort study with 
- Subjects will be randomized by systematic random sampling, according to 
registration number of the study 
- Odd numbers (Group A) will be treated with Hylan GF-20 
- Even numbers (Group B) will be treated with Methyl Prednisolone Acetate. 
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Methodology: 
 
 
 
- Patients will be given test dose of 0.5ml of Lignocaine 2% 
- They will be taken to Operation theatre and parts will be cleaned with 
Betadine and drapped with sterile towel 
- Under aseptic precautions, Lignocaine 2% will be injected to anesthetise 
the injection site 
- By following randomization procedure, either Hylan-GF20(48mg)/methyl 
prednisolone acetate(80mg) will then be infiltrated into the knee joint space 
after confirmation by aspiration technique by infero lateral approach 
- After infiltration the subjects will be observed for 15 minutes for adverse 
reactions 
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- Subjects will be asked to report immediately in case of adverse reactions 
like post injection flare (increased pain, swelling)/hypersensitivity reactions 
etc., 
- Also they will be given 3 days of analgesics and antibiotics. 
 
Inclusion criteria: 
Patients with the following criteria are included in this study. 
 Age > 45 years 
 Grade II osteoarthritis knee by Kellgren-Lawrence grading 
 Knee pain with failed conservative treatment for 1 month 
 Stiffness:<30mts 
 Crepitus 
 Bony tenderness 
 Bony enlargement 
 No palpable warmth. 
 
Exclusion criteria: 
 Post Operative cases 
 Cellulitis / Infections 
 Any implants inside. 
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 Associated with DVT calf muscles   
 Non co-operative patient     
 Low I.Q Patients /psychiatric patient 
 Trauma 
 Meniscal injury 
 Anterior/Posterior cruciate ligament injury 
 Medial/Lateral collateral ligament injury 
 Bursitis 
 Rheumatoid arthritis 
 Pseudogout 
 Other grades of osteo arthritis knee 
Patients with above criteria were excluded from this study. 
 
Sample size: 
 A total of 32 patients in hylan group and 36 patients in steroid group were 
initially enrolled, but 2 patients in hylan group and 6 patients in steroid group lost 
follow up. Hence 30 patients in each group were finally included in this study 
according to inclusion, exclusion criteria. 
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Product/Investigation details: 
All the patients who get enrolled in this study will be submitted to the following 
investigations. 
Investigations: 
FBS, PPBS, X-ray knee-AP and Lateral 
 
Product details: 
Methylprednisolone acetate – 80mg 
Hylan-GF 20 – 48mg 
 
Concomitant medications and treatment: 
 If the patient gets symptoms like pain, they will be treated with oral 
analgesics (Acetaminophen) for 3 days. The patients are advised not to take 
analgesic drugs 3 days before follow up. Also they are asked to continue isometric 
quadriceps program throughout the follow up period. 
 
Data collection and Methods: 
- Subjects will be randomized according to registration number of the study 
- Odd numbers(Group A) will be treated with Hylan GF-20 
- Even numbers(Group B) will be treated with Methyl Prednisolone Acetate 
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- Case History age, sex, duration of pain will be collected.  Anthropometric 
measurements height and weight of the patient will be collected. 
- They will be assessed with pre procedural and post procedural 
o pain score using Visual Analog Score(VAS) 
o WOMAC-C score 
o Range of Movements of Knee 
- The assessment will be analysed using SPSS software (version 21). 
 
Visual Analog Pain Score: 
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WOMAC-C SCORE: 
SL.NO. WOMAC CRITERIA NONE(1) MILD(2) MODERATE(3) SEVERE(4) 
1 Stair use Ascending     
2 Stair use Descending     
3 Rising from sitting     
4 Standing     
5 Bending     
6 Walking     
7 
Getting in-out of a 
car/bus 
    
8 Shopping     
9 Putting on socks     
10 Taking off socks     
11 Rising from bed     
12 Lying in bed     
13 Getting in / out of bath     
14 Sitting     
15 Getting on / off toilet     
16 
Heavy household 
duties 
    
17 Light household duties     
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RANGE OF MOVEMENTS: 
 Range of Movements will be assessed with use of Goniometry. 
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RESULTS AND DISCUSSION 
 
AGE: 
 
GROUP N Minimum Maximum Mean Std. 
Deviation 
HYLAN 
GROUP 
AGE 30 50 59 53.367 3.2108 
STEROID 
GROUP 
AGE 30 46 61 55.4 4.5075 
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Table 3: Demography – Age. 
Chart 2: Demography – Age. 
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 The study included patients with age ranging from 46 years to 61 years. 
After randomisation, the minimum age in the hylan group is 50 years and 
maximum age is 59 years, with median of 53.37 years. In the steroid group, the 
minimum age is 46 years and the maximum age is 61 years, with a mean of 55.4 
years. 
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SEX: 
 
GROUP   Frequency Percent Cumulative Percent 
HYLAN 
GROUP 
MALE 14 46.7 46.7 
FEMALE 16 53.3 100 
Total 30 100 
 
STEROID 
GROUP 
MALE 9 30 30 
FEMALE 21 70 100 
Total 30 100 
 
 
 
 
 
 There were 23 males and 37 females enrolled in the study, among which 14 
males (60.9% of total males) and 16 females (43.2% of total females) were 
enrolled in Hylan group and 9 males (29.1% of total males) and 21 females 
(56.8% of total females) were enrolled in the steroid group. 
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Table 4: Demography – Sex. 
Chart 3: Demography – Sex. 
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SIDE OF KNEE PAIN: 
 
GROUP  SIDE Frequency Percent 
HYLAN 
GROUP 
 
 
RIGHT 19 63.3 
   LEFT 11 36.7 
STEROID 
GROUP 
 
 
RIGHT 16 53.3 
   LEFT 14 46.7 
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Table 5: Side of knee pain. 
Chart 4: Side of knee pain. 
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 In this study, 35 patients had pain on right knee and 25 patients had pain on 
left knee. Among the patients, who were enrolled in hylan group, 19 had pain on 
right side and 11 had pain on left side. And among patients, who were enrolled in 
steroid group, 16 had pain on right side and 11 had pain on left side. 
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DURATION: 
 
GROUP DURATION(MONTHS) Frequency Percent 
HYLAN 
GROUP 
2 3 10 
  3 1 3.3 
  4 7 23.3 
  5 5 16.7 
  6 8 26.7 
  7 1 3.3 
  8 5 16.7 
    
STEROID 
GROUP 
2 1 3.3 
  3 1 3.3 
  4 3 10 
  5 7 23.3 
  6 7 23.3 
  7 6 20 
  8 5 16.7 
 
Table 6: Duration of symptoms. 
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GROUP  N Minimum Maximum Mean 
Std. 
Deviation 
HYLAN 
GROUP 
DURATION 30 2 8 5.233 1.7943 
STEROID 
GROUP 
DURATION 30 2 8 5.867 1.5477 
 
 
 
 
  
 This study included patients with knee pain for duration ranging from 2 to 8 
months, with mean in hylan group is 5.23 months and steroid group is 5.87 
months. Majority of the patients had pain for 5 to 6 months. 
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Table 7: Duration of symptoms – Mean and Standard deviation 
Chart 5: Duration of symptoms. 
49 | P a g e  
 
SITE OF KNEE PAIN: 
 
GROUP   Frequency Percent 
 
HYLAN GROUP 
MEDIAL JOINT LINE 5 16.7 
  ANTERIOR 25 83.3 
    
 
STEROID GROUP 
MEDIAL JOINT LINE 6 20 
  ANTERIOR 24 80 
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Table 8: Site of Knee pain.  
Chart 6: Site of Knee pain  
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 49 patients had pain along anterior aspect of knee joint and 11 patients had 
pain along medial joint line. Among hylan group, 25 patients had pain along 
anterior aspect and 5 had pain along medial joint line. In steroid group, 24 had 
pain along anterior aspect and 6 had pain along medial joint line. 
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SENSE OF GRINDING/LOCKING OF JOINT: 
 
 
GROUP   Frequency Percent 
HYLAN GROUP 
PRESENT 3 10 
   
  ABSENT 27 90 
    
STEROID GROUP 
PRESENT 7 23.3 
   
  ABSENT 23 76.7 
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Table 9: Sense of Grinding/Locking of knee.  
Chart 7: Sense of Grinding/Locking of knee.  
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 In this study, 50 patients (83.3%) did not have sense of grinding or locking 
of joint. 3 patients (10%) in hylan group and 7 patients (23.3%) had sense of 
grinding/locking of joint. 
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STIFFNESS: 
 
GROUP   Frequency Percent 
HYLAN GROUP 
YES 9 30 
   
  NO 21 70 
    
STEROID GROUP 
YES 14 46.7 
   
  NO 16 53.3 
 
 
 
 
 
 In this study, stiffness was present in total of 23 patients (9 in hylan group 
and 14 in steroid group). 37 patients (61.67%) did not have stiffness. 
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Table 10: Stiffness of knee  
Chart 8: Stiffness of knee.  
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COMORBIDITIES: 
 Diabetes mellitus-Type 2was the commonest comorbidity seen in this 
study. 5 patients (16.7% of steroid group) enrolled in steroid group had coronary 
artery disease associated with diabetes mellitus. 
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SWELLING OF KNEE JOINT: 
 
GROUP   Frequency Percent 
HYLAN GROUP 
PRESENT 15 50 
   
  ABSENT 15 50 
    
STEROID GROUP 
PRESENT 18 60 
   
  ABSENT 12 40 
 
 
 
 
  
 Among the patients in hylan group, 15 patients (50% of hylan group) had 
swelling over the knee joint and among steroid group, 18 patients(60% of steroid 
group) had swelling. 
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Table 11: Swelling of knee.  
Chart 9: Swelling of knee.  
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TENDERNESS: 
 
GROUP   Frequency Percent 
HYLAN 
GROUP 
PRESENT 23 76.7 
   
  ABSENT 7 23.3 
    
STEROID 
GROUP 
PRESENT 19 63.3 
   
  ABSENT 11 36.7 
 
 
 
 
 23 patients in hylan group and 19 patients in steroid group had tenderness 
over knee joint and 7 patients in hylan group and 11 patients in steroid group did 
not have tenderness over knee joint. 
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Table 12: Tenderness over knee.  
Chart 10: Tenderness over 
knee.  
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CREPITUS: 
 
GROUP   Frequency Percent 
HYLAN GROUP 
PRESENT 29 96.7 
   
  ABSENT 1 3.3 
    
STEROID GROUP 
PRESENT 21 70 
   
  ABSENT 9 30 
 
 
 
 Crepitus was felt in total of 50 patients – 29 in hylan group and 21 in 
steroid group. Crepitus was absent in 10 patients – 1 in hylan group and 9 in 
steroid group. 
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Table 13: Crepitus over knee.  
Chart 11: Crepitus over knee.  
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DEFORMITY: 
 Deformity was not present in all the patients included in this study. 
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BONY ENLARGEMENT: 
 
GROUP   Frequency Percent 
HYLAN GROUP 
PRESENT 0 0 
   
  ABSENT 30 100 
    
STEROID GROUP 
PRESENT 2 6.7 
   
  ABSENT 28 93.3 
 
 
 
 
 None of the patients in hylan group and 2 patients (6.7%) in steroid group 
had bony enlargement felt in the knee joint. 
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Table 14: Bony Enlargement.  
Chart 12: Bony Enlargement.  
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PATELLAR TAP TEST: 
 
GROUP   Frequency Percent 
HYLAN GROUP 
POSITIVE 14 46.7 
   
  NEGATIVE 16 53.3 
    
STEROID GROUP 
POSITIVE 10 33.3 
   
  NEGATIVE 20 66.7 
 
 
 
 
  
 Patellar tap test was positive in 24 patients – 14 in hylan group and 10 in 
steroid group. It was negative in 36 patients – 10 in hylan group and 20 in steroid 
group. 
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Table 15: Patellar Tap test.  
Chart 13: Patellar Tap test . 
61 | P a g e  
 
PATELLAR BULGE TEST: 
 
GROUP   Frequency Percent 
HYLAN GROUP 
POSITIVE 3 10 
   
  NEGATIVE 27 90 
    
STEROID GROUP 
POSITIVE 11 36.7 
   
  NEGATIVE 19 63.3 
 
 
 
 
 
 Patellar bulge test was positive in 14 patients – 3 in hylan group and 11 in 
steroid group. It was negative in 46 patients – 27 in hylan group and 19 in steroid 
group. 
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Table 16: Patellar Bulge test. 
Chart 14: Patellar Bulge test  
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XRAY – OSTEOPHYTES: 
 
GROUP   Frequency Percent 
HYLAN GROUP 
PRESENT 3 10 
   
  ABSENT 27 90 
    
STEROID GROUP 
PRESENT 6 20 
   
  ABSENT 24 80 
 
 
 
 
 
 Osteophytes were seen in plain x-ray of knee in 9 patients – 3 in hylan 
group and 6 in steroid group. Osteophytes were not seen in 51 patients – 27 in 
hylan group and 24 in steroid group. 
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Table 17: Presence of Osteophytes in X-ray.  
Chart 15: Presence of Osteophytes in X-ray.  
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X-RAY – JOINT SPACE NARROWING: 
 None of the patients enrolled in this study had significant joint space 
narrowing radiologically. 
 
 
 
ALLERGIC REACTIONS: 
 None of the patients included in this study developed allergic reactions 
after the intra articular injection. 
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PAIN SCORE: 
 
GROUP Statistics 
PAIN - VAS SCORE 
0 Day 
1 
week 
2 
weeks 
4 
weeks 
8 
weeks 
12 
weeks 
26 
weeks 
HYLAN 
GROUP 
Mean 8.833 8.533 7.333 6.267 3.9 2.8 2.367 
S.D. 1.1167 1.008 0.9589 1.1427 1.3481 0.9248 0.7184 
Median 9 9 8 6 4 2.5 2 
STEROID 
GROUP 
Mean 9.667 8.4 6.7 5 3.867 6.567 6.833 
S.D. 0.6065 0.8944 0.9879 0.8305 1.306 1.7555 1.7237 
Median 10 8 7 5 4 7 7 
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Table 18: Pain score (VAS) in the follow up period.  
Chart 16: Pain score (VAS) in the follow up. 
period  
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 Pain was assessed using Visual Analog Scoring (VAS) in this study. It 
showed significant pain relief with hylan group over due course of time. In steroid 
group, there was initial pain response till 8 weeks after the treatment, but later the 
pain score started to show upward trend in later weeks. In conclusion, pain relief 
was better in hylan group than steroid group with p value <0.05 in all the follow 
up period except 8
th
 week. 
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WOMAC SCORE: 
 
GROUP Statistic 
WOMAC SCORE 
0 Day 
1 
week 
2 
weeks 
4 
weeks 
8 weeks 
12 
weeks 
26 
weeks 
HYLAN 
GROUP 
Mean 59.4 58.8 53.8 45.9 29.133 18 15.4 
S.D. 8.3236 8.227 9.5282 9.9874 10.2309 6.7722 6.1341 
Median 63 62 59 50 30 20 17.5 
STEROID 
GROUP 
Mean 61.1 54.5 46.2 35.533 28.433 40.3 44.433 
S.D. 5.2807 5.2703 7.5265 9.0848 11.1035 11.3111 13.2318 
Median 62 55 48 40 30 41 48 
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Table 19: WOMAC-C score in the follow up period.  
Chart 17: WOMAC-C score in the follow up period. 
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 Functional assessment after the treatment was done using WOMAC score 
(The Western Ontario and McMaster Universities Arthritis Index) and 
improvement in range of movements of the knee in this study. It showed 
significant functional improvement with hylan group over due course of time. In 
steroid group, there was initial better response till 8 weeks, but later the functional 
ability started to reduce in later weeks. In conclusion, functional improvement as 
per WOMAC score was better in hylan group than steroid group with p value 
<0.05. 
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RANGE OF MOVEMENTS(ROM) OF KNEE: 
 
GROUP Statistic 
ROM SCORE 
0 Day 1 week 
2 
weeks 
4 
weeks 
8  
weeks 
12 
weeks 
26 
weeks 
HYLAN 
GROUP 
Mean 76.667 76.667 80.333 91.667 102.333 103.333 103.333 
S.D. 8.4418 8.4418 7.6489 5.9209 5.0401 4.7946 4.7946 
Median 70 70 80 90 100 100 100 
STEROID 
GROUP 
Mean 79.333 76.8 84.333 93 92 82.333 82.333 
S.D. 9.4443 20.5534 9.3526 9.8786 11.5669 12.5075 12.5075 
Median 80 80 80 90 90 80 80 
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Table 20: range of Movements of Knee in the follow up period. 
Chart 18: Range of Movements of Knee in the follow up period.  
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 Functional assessment after the treatment was also done using range of 
movements (ROM). It showed significant improvement in ROM with hylan group 
over due course of time and remained stable in 12
th
 and 26
th
 weeks. In steroid 
group, there was initial better response around 4
th
 and 8th weeks, but later ROM 
got reduced and did not show any further change in later weeks. In conclusion, 
functional improvement as per ROM was better in hylan group than steroid group 
with p value <0.05. 
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DISCUSSION 
 
 As we all know about the chronic nature of the disease causing chronic 
disability with functional impairment, we are concerned about the possible side 
effects of selective and non selective analgesics, non pharmacological treatment. 
Hence physicians were increasingly considering intraarticular treatment with 
steroids or visco supplementation.  
 
 The study included patients with age ranging from 46 years to 61 years. 
After randomisation, the minimum age in the hylan group is 50 years and 
maximum age is 59 years, with median of 53.37 years. In the steroid group, the 
minimum age is 46 years and the maximum age is 61 years, with a mean of 55.4 
years. 
 There were 23 males and 37 females enrolled in the study, among which 14 
males (60.9% of total males) and 16 females (43.2% of total females) were 
enrolled in Hylan group and 9 males (29.1% of total males) and 21 females 
(56.8% of total females) were enrolled in the steroid group. 
 In this study, 35 patients had pain on right knee and 25 patients had pain on 
left knee. Among the patients, who were enrolled in hylan group, 19 had pain on 
right side and 11 had pain on left side. And among patients, who were enrolled in 
steroid group, 16 had pain on right side and 11 had pain on left side. 
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 This study included patients with knee pain for duration ranging from 2 to 8 
months, with mean in hylan group is 5.23 months and steroid group is 5.87 
months. Majority of the patients had pain for 5 to 6 months. 
 49 patients had pain along anterior aspect of knee joint and 11 patients had 
pain along medial joint line. Among hylan group, 25 patients had pain along 
anterior aspect and 5 had pain along medial joint line. In steroid group, 24 had 
pain along anterior aspect and 6 had pain along medial joint line. 
 In this study, 50 patients (83.3%) did not have sense of grinding or locking 
of joint. 3 patients (10%) in hylan group and 7 patients (23.3%) had sense of 
grinding/locking of joint. 
 In this study, stiffness was present in total of 23 patients (9 in hylan group 
and 14 in steroid group). 37 patients (61.67%) did not have stiffness. 
 Diabetes mellitus-Type 2was the commonest comorbidity seen in this 
study. 5 patients (16.7% of steroid group) enrolled in steroid group had coronary 
artery disease associated with diabetes mellitus. 
 Among the patients in hylan group, 15 patients (50% of hylan group) had 
swelling over the knee joint and among steroid group, 18 patients (60% of steroid 
group) had swelling. 
 23 patients in hylan group and 19 patients in steroid group had tenderness 
over knee joint and 7 patients in hylan group and 11 patients in steroid group did 
not have tenderness over knee joint. 
72 | P a g e  
 
 Crepitus was felt in total of 50 patients – 29 in hylan group and 21 in 
steroid group. Crepitus was absent in 10 patients – 1 in hylan group and 9 in 
steroid group. 
 Deformity was not present in all the patients included in this study. 
 None of the patients in hylan group and 2 patients (6.7%) in steroid group 
had bony enlargement felt in the knee joint. 
 Patellar tap test was positive in 24 patients – 14 in hylan group and 10 in 
steroid group. It was negative in 36 patients – 10 in hylan group and 20 in steroid 
group. 
 Patellar bulge test was positive in 14 patients – 3 in hylan group and 11 in 
steroid group. It was negative in 46 patients – 27 in hylan group and 19 in steroid 
group. 
 Osteophytes were seen in plain x-ray of knee in 9 patients – 3 in hylan 
group and 6 in steroid group. Osteophytes were not seen in 51 patients – 27 in 
hylan group and 24 in steroid group. 
 None of the patients enrolled in this study had significant joint space 
narrowing radiologically. 
 None of the patients included in this study developed allergic reactions 
after the intra articular injection. 
 Pain was assessed using Visual Analog Scoring (VAS) in this study. It 
showed significant pain relief with hylan group over due course of time. In steroid 
group, there was initial pain response till 8 weeks after the treatment, but later the 
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pain score started to show upward trend in later weeks. In conclusion, pain relief 
was better in hylan group than steroid group with p value <0.05 in all the follow 
up period except 8
th
 week. 
 Functional assessment after the treatment was done using WOMAC score 
(The Western Ontario and McMaster Universities Arthritis Index) and 
improvement in range of movements of the knee in this study. It showed 
significant functional improvement with hylan group over due course of time. In 
steroid group, there was initial better response till 8 weeks, but later the functional 
ability started to reduce in later weeks. In conclusion, functional improvement as 
per WOMAC score was better in hylan group than steroid group with p value 
<0.05. 
 Functional assessment after the treatment was also done using range of 
movements (ROM). It showed significant improvement in ROM with hylan group 
over due course of time and remained stable in 12
th
 and 26
th
 weeks. In steroid 
group, there was initial better response around 4
th
 and 8th weeks, but later ROM 
got reduced and did not show any further change in later weeks. In conclusion, 
functional improvement as per ROM was better in hylan group than steroid group 
with p value <0.05. 
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CONCLUSIONS 
 
From this study, we conclude the following: 
 Intra articular Hylan GF-20 (48mg) shows statistically significant 
improvement in Pain in analyzing the patients with Visual Analog Score 
(VAS). 
 Similarly, there is improvement in range of movements and WOMAC score 
(C domain) in hylan group. 
 For steroid group, there is initial statistical improvement upto 8 weeks in 
pain and other functional components, but after 8 weeks, there is no clinical 
improvement. 
 Hence Hylan GF-20 can be considered as an important therapeutic measure 
in the management of OA knee. 
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LIMITATIONS 
 
 Smaller sample size. 
 No long term follow up – more than 26 weeks. 
 Radiological follow up not done. 
 Pathological improvement/arrest not documented. 
 Effect of treatment in severe grades of OA knee not been studied. 
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SCOPE FOR FUTURE STUDY 
 
 Long term follow up. 
 Correlation of clinical improvement to radiological improvement. 
 Correlation with arthroscopic analysis. 
 Gene therapy – to arrest pathophysiology of OA knee. 
 Mesenchymal stem cell therapy – for regeneration of diseased cartilage. 
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ANNEXURE-I 
STUDY PROFORMA 
Name:     Age:  Sex:  Occupation:  
  
OP number:     Thesis Registration number: 
Address:            
Contact number 
Height:  cm  Weight: kg  BMI:      BP:  mmHg 
 
Complaints 
Knee pain: Right ⊡  Left⊡          
Duration:______days/months/years Pain Score: VAS ____/10 
Site of Pain: Anterior ⊡  MJL ⊡ 
Aggravating factors: ⊡ If yes, __________________________________________  Relieving factors: 
⊡If yes, _______________________________________ 
Sense of grinding or locking of a joint: ⊡  
Stiffness: ⊡If yes, duration: _____days/months/years 
Co-Morbidities: Diabetes mellitus: ⊡ Systemic hypertension: ⊡  
   Coronary artery disease: ⊡  
Examination 
Inspection: Swelling ⊡  
Palpation on standing /supine:  Tenderness⊡ Crepitus ⊡ Deformity: T.Varum⊡ 
     G.varum⊡ G.valgum⊡ 
Bony enlargement⊡ Patellar tap test⊡ Patellar bulge test⊡  
Investigations: FBS:____mg/dl PPBS: _____mg/dl   X-ray –Knee: Osteophytes ⊡  
    Joint space narrowing⊡ 
Management: Intra articular Hylan-GF-20  Injection⊡  
  Intra articular steroid (methyl prednisolone acetate)⊡  
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 0 day 1 
weeks 
2 
weeks 
4 
weeks 
6 
weeks 
8 
weeks 
12 
weeks 
26 
weeks 
Pain score 
(VAS) 
        
WOMAC score         
Knee ROM         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exclusion criteria: 
• Trauma / Meniscal injury / Ligament 
Injury 
• Bursitis 
• Rheumatoid arthritis 
• Pseudogout 
• Post Operative cases 
• Cellulitis / Infections 
• Any implants inside 
• Associated with DVT - calf muscles   
• Non co-operative patient     
• Low I.Q Patients /psychiatric patient 
• Other grades of osteo arthritis knee 
Inclusion criteria: 
• Grade II osteoarthritis 
knee by Kellgren-
Lawrence grading 
• Knee pain with failed 
conservative treatment 
for 1 month associated 
with 
• Age:>50 years 
• Stiffness:<30mts 
• Crepitus  
• Bony tenderness 
• Bony enlargement 
• No palpable warmth 
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ANNEXURE-II 
 
PATIENT INFORMATION SHEET 
 
TITLE OF THE STUDY: Comparison of functional outcome of Intra articular Hylan 
GF-20 Vs Methyl Prednisolone Acetate for Grade II Osteo arthritis – knee 
 
We are conducting a study on “Comparison of functional outcome of Intra articular 
Hylan GF-20 Vs. on Methyl Prednisolone Acetate for Grade II Osteo arthritis - 
knee” among patients in the Government Institute of Rehabilitation Medicine, Madras 
Medical College, Chennai. 
 
The purpose of this study is to compare the clinical outcome of Intra articular Hylan GF-
20 Vs Methyl Prednisolone Acetate for Grade II Osteo arthritis - knee.  
 
We are selecting patients more than 50 years with Grade II Osteo arthritis – knee. We 
perform intra articular injection with Hylan GF-20 or Methyl Prednisolone Acetate, 
which in any way do not affect our final report or  ;;;; management. 
 
The  privacy  of  the  patients  in  the  research  will  be  maintained   throughout   the 
study. In the event of any publication or presentation resulting from the research, no 
personally identifiable information will be shared. 
 
Taking part in this study is voluntary.  You  are  free  to  decide  to  participate in this  
study  or  to  withdraw  at  any  time;  your  decision  will  not  result  in any  loss of  
benefits to which  you  are  otherwise  entitled.  
The  results  of  the  special  study  may  be  intimated  to  you  at  the  end  of the study 
period  or during   the study if  anything  is found  abnormal  which  may  aid  in  the  
management  or treatment. 
 
 
 
Signature of Participant          Signature of 
Investigator               
(DR.S.SUGANTHI) 
 
Date : 
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PATIENT CONSENT FORM 
 
Study Detail : Comparison of functional outcome of Intra articular Hylan 
GF-20 Vs Methyl Prednisolone Acetate for Grade II Osteo 
arthritis – knee 
 
Study Centre : Government Institute of Rehabilitation Medicine, Chennai. 
 
Patient’s Name :  
 
Patient’s Age :  
 
Identification 
Number 
:  
 
Check (√) these boxes 
 
I confirm that I have understood the purpose of procedure for the above study. I have the 
opportunity to ask question and all my questions and doubts have been answered to my 
complete satisfaction.  
 
I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time without giving reason, without my legal rights being affected.  
 
I understand that sponsor of the clinical study, others working on the sponsor’s behalf, the 
ethical committee and the regulatory authorities will not need my permission to look at my 
health records, both in respect of current study and any further research that may be 
conducted in relation to it, even if I withdraw from the study I agree to this access. 
However, I understand that my identity will not be revealed in any information released to 
third parties or published, unless as required under the law. I agree not to restrict the use of 
any data or results that arise from this study.  
 
I agree to take part in the above study and to comply with the instructions given during the 
study and faithfully cooperate with the study team and to immediately inform the study 
staff if I suffer from any deterioration in my health or wellbeing or any unexpected or 
unusual symptoms.  
 
I hereby consent to participate in this study.  
 
I hereby give permission to undergo detailed clinical examination, Radiographs, blood 
investigations and surgical procedure as required.  
 
 
 
Signature/thumb impression  Signature of Investigator 
Patient’s Name and Address:  Study Investigator’s Name: Dr.S.SUGANTHI 
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ந ோயோளிகள் தகவல் தோள் 
 
கற்கக தகயப்பு: முறங்கால் கீல்லாதம் சிகிச்கசக்கான சச஬ல்பாட்டு 
முன்னனற்ம ஒப்படீு(Intra articular Hylan GF-20 Vs Methyl Prednisolone Acetate) 
 
சசன்கன ஫ருத்துலக் கல்லூரி஬ின் கீழ் இ஬ங்கி லரும் அ஭சு புனர் லாழ்வு 
஫ருத்துல நிறுலனத்தில் முறங்கால் கீழ்லாதத்திற்கான சிகிச்கச஬ில் 
ஆய்வு நடத்தி லருகின்னமாம். 
 
இந்த ஆய்லின் னநாக்கம் மூட்டுக்குள் Hylan GF-20 அல்யது ஫ீத்கதல் 
ப்ச஭ட்னினசானயான் (Methyl Prednisolone Acetate) ஫ருந்து சசலுத்துலதன் 
மூயம் ஏற்படும் சச஬ல்பாட்டு லிகரவு ஒப்படீு ஆகும். 
 
னநா஬ாரிகரின் தனிம௃ரிக஫ இந்த ஆய்வு முழுலதும் பாதுகாக்கப்படும். 
 
இந்த சிகிச்கச஬ில் பங்கு சகாள்ர முழு ஫னதுடனும், சு஬நிகனவுடனும் 
எந்த லித லற்புறுத்தயின்மி சம்஫திக்கின்னமன். 
 
இந்த னநாய் ஫ற்றும் சிகிச்கச சதாடர்பான லிரக்கங்கள் ஫ற்றும் பின் 
லிகரவுககரம௃ம் ஫ருத்துலர் மூயம் அமிந்து சகாண்னடன். 
 
 
 
 
பங்கு சபறுபலரின் ககச஬ாப்பம்       ஆய்லாரரின் 
ககச஬ாப்பம்  
      (டாக்டர் எஸ்.சுகந்தி) 
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ந ோயோளிகளின் ஒப்புதல் படிவம் 
 
ஆய்வு : முறங்கால் கீல்லாதம் சிகிச்கசக்கான சச஬ல்பாட்டு முன்னனற்ம 
ஒப்படீு 
 
ஆய்வு மையம் : அ஭சு புனர் லாழ்வு ஫ருத்துல நிறுலனம், சசன்கன 
஫ருத்துலக் கல்லூரி, சசன்கன. 
 
ந ோயோளியின் பபயர் : 
 
வயது :  
 
ைருத்துவைமை பதிவு எண் : 
 
ஆய்வின் பதிவு எண் : 
 
இந்த கட்டங்கரில் (√) இடுக: 
 
நான் இந்த ஆய்லின் னநாக்கம் பற்மி அமிந்து சகாண்னடன். எனது 
சந்னதகங்ககர சதரிலாக னகட்டு சதரிந்து சகாண்னடன்.                      
 
இந்த ஆய்லில் பங்னகற்பதும், ஆய்லியிருந்து எந்த னந஭த்திலும் லியகிக் 
சகாள்லதும் எனது தனிப்பட்ட உரிக஫ என்பகதம௃ம் சதரிந்து சகாண்னடன்.                                
 
ஆய்லாரர், சநமிமுகமக் குழு ஫ற்றும் கட்டுப்பாட்டு அதிகாரிகள் எனது 
஫ருத்துல தகலல்ககர சதரிந்து சகாள்ர அனு஫தி அரிக்கின்னமன்.                                    
 
னநா஬ாரிகரின் தனிம௃ரிக஫ இந்த ஆய்வு முழுலதும் பாதுகாக்கப்படும் 
என்பகத சதரிந்து சகாண்னடன்.                                     
   
இந்த ஆய்லில் கயந்து சகாள்ர முழு ஒப்புதல் அரிக்கினமன்.      
 
 
பங்கு சபறுபலரின் ககச஬ாப்பம்   ஆய்லாரரின் ககச஬ாப்பம்  
னநா஬ாரி஬ின் சப஬ர் ஫ற்றும் முகலரி (டாக்டர்.எஸ்.சுகந்தி) 
 
னததி: 
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ANNEXURE-III 
 
MASTER CHART 
 
Keys to master chart 
 
 
RANDOM NO: 
 1 - HYLAN (HYLAN-GF 20 – 48mg) GROUP 
 2 - STEROID (METHYLPREDNISOLONE ACETATE –  
80mg) GROUP 
 
SEX: 
1 - MALE 
2 - FEMALE 
 
SIDE OF KNEE PAIN: 
1 - RIGHT 
2 - LEFT 
 
SITE OF PAIN: 
1 - MEDIAL JOINT LINE 
2 - ANTERIOR 
 
SENSE OF GRINDING/LOCKING OF JOINT: 
1 - YES 
2 - NO 
 
STIFFNESS: 
1 - YES 
2 - NO 
 
SWELLING: 
1 - YES 
2 - NO 
 
TENDERNESS: 
1 - YES 
2 - NO 
 
CREPITUS: 
1 - YES 
2 - NO 
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DEFORMITY: 
 0 - NO 
1 - VARUS 
2 - VALGUS 
 
 
 
BONY ENLARGEMENT: 
1 - YES 
2 - NO 
 
PATELLAR TAP TEST: 
1 - POSITIVE 
2 - NEGATIVE 
 
PATELLAR BULGE TEST: 
1 - POSITIVE 
2 - NEGATIVE 
 
X RAY-OSTEOPHYTES: 
1 - YES 
2 - NO 
 
X RAY-JOINT SPACE NARROWING: 
1 - YES 
2 - NO
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1 6351 1 50 2 1 6 1 2 1 1 1 1 0 2 1 2 151 238 1 1 10 9 7 6 4 3 3 60 60 60 50 33 20 10 70 70 70 90 110 110 110
2 2055 2 50 2 1 5 2 2 2 1 2 1 0 2 2 1 92 106 2 1 10 8 7 5 7 7 7 66 60 50 40 48 55 55 70 80 90 90 70 70 70
3 6346 1 55 2 2 2 2 2 1 2 1 1 0 2 2 2 88 121 2 1 9 8 8 6 2 2 2 51 51 50 45 36 25 25 70 70 80 100 110 110 110
4 1631 2 61 1 1 6 2 2 1 1 2 2 0 2 1 2 72 88 2 1 10 9 7 5 6 7 7 64 50 44 36 48 50 55 90 90 90 100 90 90 90
5 6350 1 50 2 2 6 2 2 2 1 2 1 0 2 1 2 95 152 2 1 9 9 8 6 4 2 2 67 67 60 50 30 20 20 90 90 90 100 110 110 110
6 1766 2 59 1 2 6 2 2 1 2 2 1 0 2 2 2 70 88 1 1 9 8 5 5 4 6 6 60 55 50 42 30 30 25 90 90 100 100 100 80 80
7 7986 1 50 2 1 6 2 2 1 1 1 1 0 2 1 2 151 287 1 1 6 6 5 4 2 2 2 47 46 40 30 25 10 10 100 100 100 100 100 100 100
8 1389 2 60 2 2 8 1 1 1 2 1 1 0 2 2 2 100 110 2 1 10 7 6 5 4 8 8 62 55 48 40 20 40 48 80 80 80 110 110 90 90
9 6348 1 59 1 1 2 2 2 1 1 1 1 0 2 1 2 97 145 2 1 7 7 6 5 3 3 2 41 41 30 22 10 10 8 90 90 90 100 100 100 100
10 390 2 50 2 2 2 2 2 2 1 2 1 0 2 2 1 80 96 2 1 10 10 9 7 3 8 9 56 48 36 20 18 32 48 70 7 80 90 90 70 70
11 1394 1 54 1 2 3 2 2 2 2 2 1 0 2 2 2 76 90 2 1 9 8 6 5 4 2 2 60 58 58 54 10 10 8 70 70 70 90 100 100 100
12 1437 2 60 1 2 5 2 2 2 1 1 1 0 1 2 2 92 106 2 1 10 8 7 5 3 7 7 66 60 50 40 30 55 55 70 80 80 90 90 70 70
13 6347 1 50 2 2 8 1 1 1 2 1 1 0 2 2 2 190 360 1 1 10 10 8 6 2 2 2 63 62 60 50 25 10 10 70 70 80 90 100 100 100
14 988 2 55 2 1 8 2 2 2 1 1 1 0 2 1 2 72 88 2 1 10 9 7 5 4 7 7 64 50 44 36 30 50 55 90 90 90 100 90 90 90
15 5121 1 55 1 1 8 2 2 2 2 1 1 0 2 2 2 70 121 2 1 9 9 8 6 4 2 2 63 62 60 50 25 10 10 80 80 80 90 100 100 100
16 4261 2 46 2 1 5 2 2 2 2 1 2 0 2 2 1 79 88 2 1 9 8 5 5 4 6 6 60 55 50 42 30 30 45 90 90 100 100 80 80 80
17 6987 1 52 1 1 6 2 2 2 2 1 1 0 2 2 2 78 101 2 1 9 8 7 6 2 2 2 63 62 60 50 25 10 10 70 70 70 80 100 100 100
18 5950 2 50 2 2 7 2 2 2 1 1 2 0 2 2 1 100 110 2 1 10 7 6 5 4 8 8 62 55 48 40 20 40 48 80 80 80 110 110 90 90
19 7101 1 58 2 1 4 2 2 2 2 2 1 0 2 2 2 108 140 2 1 10 9 7 6 4 3 3 60 60 60 50 33 20 20 70 70 80 90 110 110 110
20 5059 2 60 2 1 6 2 2 1 1 1 2 0 2 2 1 80 96 2 1 8 7 7 3 2 7 7 56 48 36 20 18 32 48 80 80 80 90 100 80 80
21 8200 1 59 1 1 4 2 2 2 1 2 1 0 2 1 2 80 90 2 1 9 9 8 8 6 4 2 63 63 60 55 40 20 20 80 80 80 90 100 100 100
22 3142 2 50 1 1 7 2 2 2 1 1 2 0 2 1 2 92 106 2 1 10 8 6 5 3 6 6 66 60 50 40 48 55 55 70 80 90 90 70 70 70
23 8305 1 50 2 1 8 1 1 1 2 1 1 0 2 2 2 70 100 2 1 9 9 8 7 4 3 3 65 63 55 50 30 20 10 70 70 80 90 100 100 100
24 6177 2 57 2 2 4 2 1 1 2 2 1 0 2 2 2 72 88 1 1 10 9 7 5 4 7 7 64 50 44 36 30 50 55 90 90 90 100 90 90 90
25 8402 1 51 2 2 5 1 2 2 2 2 1 0 2 2 2 72 104 2 1 10 9 7 7 4 2 2 62 60 58 52 30 15 15 70 70 80 80 100 100 100
26 6550 2 54 2 2 6 1 1 1 2 2 1 0 2 2 2 76 90 2 1 10 8 7 5 7 7 7 66 60 50 40 48 55 55 70 70 70 80 70 70 70
27 5105 1 54 2 1 6 2 2 2 2 2 1 0 2 2 2 80 98 2 1 9 9 8 7 3 2 2 64 60 54 40 15 10 10 70 70 90 90 100 100 100
28 3142 2 50 1 1 7 2 2 2 1 1 2 0 2 1 2 90 100 2 1 9 8 6 5 2 4 7 66 55 48 45 50 50 64 90 90 70 70 80 80 80
29 8146 1 52 1 1 8 2 2 2 1 1 1 0 2 1 2 95 152 2 1 9 9 8 6 4 2 2 67 67 60 50 30 20 20 90 90 90 100 110 110 110
30 6170 2 57 2 2 3 1 1 2 2 2 1 0 2 2 1 74 80 1 1 9 8 6 5 2 4 7 66 55 48 45 15 50 64 90 90 70 70 80 80 80
MASTER CHART
PAIN SCORE(VAS) WOMAC SCORE KNEE ROM
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31 4891 1 58 1 1 6 2 2 2 2 1 1 0 2 2 1 190 360 2 1 10 10 8 6 2 2 2 63 62 60 50 25 10 10 70 70 80 90 100 100 100
32 7255 2 50 2 2 8 1 1 2 2 1 1 0 2 2 1 78 92 2 1 10 9 7 4 4 8 8 60 60 50 30 15 45 50 70 70 80 80 90 70 70
33 6795 1 50 2 1 4 2 2 2 2 1 1 0 2 1 1 95 152 2 1 9 9 8 6 4 2 2 67 67 60 50 30 20 20 70 70 70 100 110 110 110
34 6738 2 55 2 1 5 2 2 2 1 1 2 0 2 1 2 90 108 2 1 10 9 7 4 4 8 8 60 60 50 30 15 45 50 70 70 80 80 90 70 70
35 7543 1 55 1 1 5 2 2 2 1 1 1 0 2 1 2 78 100 2 1 9 9 8 7 4 3 3 65 63 55 50 30 20 10 70 70 80 90 100 100 100
36 7934 2 60 2 1 6 2 2 1 1 1 1 0 2 2 1 78 84 2 1 10 9 7 4 3 9 9 48 48 36 25 20 42 42 70 70 70 80 90 70 70
37 9205 1 59 1 1 7 2 2 2 1 1 1 0 2 2 2 80 90 2 1 9 9 8 8 6 4 2 63 63 60 55 40 20 10 80 80 80 90 100 100 100
38 4002 2 60 1 2 5 2 2 2 2 1 1 0 2 2 2 80 94 2 1 10 9 7 4 3 9 9 48 48 36 25 20 42 42 70 70 70 80 80 70 70
39 8567 1 54 1 1 8 2 2 2 1 1 1 0 2 1 2 100 140 2 1 10 9 7 6 4 3 3 60 60 60 50 33 20 20 70 70 70 90 110 110 110
40 6489 2 52 2 1 7 2 2 1 1 1 1 0 2 1 2 79 88 2 1 8 7 5 4 3 8 8 52 50 30 20 15 47 47 90 90 90 90 110 90 90
41 5579 1 56 2 2 6 2 2 2 2 2 1 0 2 2 2 95 152 2 1 9 9 8 6 4 2 2 67 67 60 50 30 20 20 80 80 90 100 110 110 110
42 8530 2 60 2 1 8 2 2 1 1 1 2 0 2 1 1 80 92 2 1 10 8 7 5 3 7 7 66 60 60 40 38 55 55 70 80 90 90 70 70 70
43 6907 1 51 1 1 4 2 2 2 1 1 1 0 2 1 2 151 287 2 1 6 6 5 4 2 2 2 47 46 40 30 25 10 10 80 80 80 90 100 100 100
44 4836 2 55 2 2 4 2 1 1 2 1 1 0 2 2 2 90 106 1 1 10 9 7 5 6 7 7 64 50 44 36 38 50 55 90 90 90 100 90 90 90
45 7562 1 57 1 1 4 2 2 2 2 1 1 0 2 2 2 97 145 2 1 7 7 6 5 3 2 2 41 41 30 22 10 10 8 90 90 90 100 100 100 100
46 8984 2 58 2 1 6 2 2 2 2 1 1 0 2 2 1 96 103 2 1 10 10 7 6 3 8 9 56 48 36 20 18 32 48 70 70 80 90 90 70 70
47 7998 1 53 2 2 5 2 2 2 2 1 1 0 2 2 2 80 98 2 1 9 9 8 8 6 4 2 63 63 60 55 40 20 20 80 80 80 90 100 100 100
48 8060 2 60 1 1 6 1 2 1 1 1 1 0 2 1 2 151 238 1 1 10 9 7 6 4 3 3 60 60 60 50 33 20 10 70 70 70 90 110 110 110
49 9105 1 51 2 2 2 1 1 2 2 1 2 0 2 2 2 151 238 2 1 10 9 7 6 4 3 3 60 60 60 50 33 20 20 70 70 80 90 110 110 110
50 1792 2 60 2 2 5 2 2 1 1 2 2 0 2 1 2 72 88 2 1 10 9 7 5 6 7 7 64 50 44 36 48 50 55 90 90 90 100 90 90 90
51 8125 1 50 1 1 4 2 2 2 1 1 1 0 2 2 1 85 121 2 1 9 8 8 6 2 2 2 51 51 50 45 36 20 20 70 70 70 90 90 110 110
52 10376 2 55 1 2 8 2 2 2 1 2 1 0 2 1 2 95 152 2 1 9 9 8 6 4 2 2 67 67 60 50 30 20 20 90 90 90 100 110 110 110
53 7559 1 56 1 1 6 2 2 2 1 1 1 0 2 1 2 97 145 2 1 7 7 6 5 3 2 2 41 41 32 22 10 10 8 70 70 70 80 100 110 110
54 10343 2 58 2 1 5 2 2 1 2 2 1 0 2 2 2 70 88 1 1 9 8 5 5 4 6 6 60 55 50 42 30 30 25 90 90 100 100 100 80 80
55 163 1 50 2 2 4 2 2 1 1 1 1 0 2 1 2 84 98 2 1 9 9 8 8 6 4 2 66 66 54 50 45 30 20 80 80 80 90 100 100 100
56 10113 2 50 2 2 7 1 1 1 2 1 1 0 2 2 2 100 110 2 1 10 7 6 5 4 8 8 62 55 48 40 20 40 48 80 80 80 110 110 90 90
57 589 1 50 2 2 5 2 2 1 1 1 1 0 2 1 2 74 96 2 1 9 9 8 8 6 4 2 66 66 54 50 45 30 20 80 80 80 90 100 100 100
58 5310 2 60 2 1 4 2 2 2 1 2 1 0 2 2 1 80 96 2 1 10 10 9 7 3 8 9 56 48 36 20 18 32 48 70 7 80 90 90 70 70
59 590 1 52 2 2 5 2 2 1 1 1 1 0 2 1 2 78 92 2 1 9 9 8 8 6 4 2 66 66 54 50 45 30 20 80 80 80 90 100 100 100
60 6767 2 50 1 1 7 2 2 2 1 1 1 0 1 2 2 92 106 2 1 10 8 7 5 3 7 7 66 60 50 40 30 55 55 70 80 80 90 90 70 70
PAIN SCORE(VAS) WOMAC SCORE KNEE ROM
